Core Insights - BioCardia, Inc. reported its financial results for the year ended December 31, 2025, highlighting advancements in its CardiAMP and CardiALLO cell therapies for cardiovascular diseases [1][9][14]. Financial Performance - The company had no revenues in 2025, down from $58,000 in 2024, primarily due to the fulfillment of performance obligations [16]. - Research and development expenses increased to approximately $5.0 million in 2025 from $4.4 million in 2024, driven by activities related to the CardiAMP Heart Failure Trial [16]. - Selling, general and administrative expenses decreased to approximately $3.3 million in 2025 from $3.7 million in 2024 [16]. - The net loss for 2025 was approximately $8.2 million, compared to $7.9 million in 2024 [16]. Clinical Developments - The CardiAMP autologous cell therapy for ischemic heart failure is advancing regulatory discussions with the FDA and Japan's PMDA, alongside the confirmatory CardiAMP HF II Trial [3][5]. - Positive results from the CardiAMP trial showed an average increase of 107 seconds in exercise tolerance and an 82% reduction in angina episodes at the six-month follow-up [4]. - The company is preparing to submit a Q-Sub request to the FDA regarding the CardiAMP System's approvability based on safety and efficacy signals from clinical trials [5][10]. Upcoming Milestones - Anticipated milestones include the CardiAMP for Ischemic HFrEF FDA Q-Sub on Approval Pathway in Q1 2026 and a formal clinical consultation with Japan's PMDA in Q2 2026 [16]. - An oral presentation of CardiAMP for Chronic Myocardial Ischemia is scheduled for Euro PCR in Q2 2026 [16]. - A Pre-Submission meeting with the FDA regarding the Helix transendocardial delivery system is also planned for Q2 2026 [10][16]. Company Overview - BioCardia is focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with its main platforms being CardiAMP and CardiALLO cell therapies [14]. - The company utilizes its Helix biotherapeutic delivery system and Morph vascular navigation product platforms to enhance treatment efficacy [14].

Core Insights - BioCardia, Inc. has reported promising late-breaking echocardiography results from its Phase III clinical trial for ischemic heart failure with reduced ejection fraction (HFrEF), indicating a potential reduction in negative remodeling of heart volumes in treated patients [1][3]. Clinical Results - The clinical results were presented by Dr. Amish Raval at the Technology and Heart Failure Therapeutics (THT) conference, highlighting the effectiveness of autologous CardiAMP cell therapy in reducing pathological left ventricular remodeling over time compared to control patients [2][3]. - Treated patients showed a statistically significant reduction in left ventricular end diastolic volume (p = 0.06) and left ventricular end systolic volume (p = 0.09), with clinically meaningful differences in a subgroup with elevated biomarkers of heart stress [3][4]. Treatment Implications - CardiAMP treatment is associated with less adverse cardiac remodeling in patients with elevated NTproBNP levels, a biomarker of myocardial stress, suggesting its potential benefits in targeted patient subgroups [4][5]. - The results from the CardiAMP-HF trial indicate a promising avenue for addressing the growing burden of heart failure, particularly as current pharmaceutical options have limited impact [5]. Company Overview - BioCardia is a leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with its CardiAMP autologous cell therapy receiving FDA Breakthrough designation [6][7]. - The company is developing three cardiac clinical stage product candidates and utilizes advanced biotherapeutic delivery platforms [7].

Core Insights - BioCardia, Inc. announced that echocardiography data for its CardiAMP Cell Therapy for heart failure has been accepted for presentation at the THT Meeting in March 2026 [1][2] Group 1: CardiAMP Cell Therapy - CardiAMP Cell Therapy is designed to use a patient's own bone marrow cells to improve heart function through a minimally invasive procedure [3] - The therapy aims to increase capillary density and reduce tissue fibrosis in myocardial tissue, addressing microvascular dysfunction [3] - The clinical development of CardiAMP is supported by the Maryland Stem Cell Research Fund and is reimbursed by CMS [3] Group 2: Company Overview - BioCardia is a leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with multiple clinical-stage product candidates [4] - The company has developed biotherapeutic platforms, including CardiAMP and CardiALLO™, and utilizes advanced delivery systems like Helix™ and Morph [4] - BioCardia is actively seeking partnerships for biotherapeutic delivery with other companies in the biologic therapy space [4]

Core Insights - BioCardia, Inc. has completed a third preliminary clinical consultation with Japan's PMDA regarding its CardiAMP Cell Therapy for treating Heart Failure with Reduced Ejection Fraction (HFrEF) [1] - The PMDA has indicated that BioCardia can proceed to formal clinical consultation, which may lead to regulatory approval in Japan if the data is deemed sufficient [1] Company Overview - BioCardia, Inc. is a leader in cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases [5] - The company is headquartered in Sunnyvale, California, and focuses on developing autologous and allogeneic cell therapies [5] Product Development - CardiAMP Cell Therapy utilizes a patient's own bone marrow cells delivered via a minimally invasive procedure to improve heart function [3] - The therapy has received FDA Breakthrough designation and is supported by the Maryland Stem Cell Research Fund [3] Clinical Trial Highlights - Phase 1: TABMMI Heart Failure Trial involved 20 patients [4] - Phase 2: TACHFT Trial included 33 patients, with 29 randomized [4] - Phase 3: CardiAMP HF Trial had 125 patients, with 115 randomized and a 24-month follow-up [4] - Key outcomes include a 90% survival rate at three years and a 7% improvement in left ventricular ejection fraction at 24 months (p=0.001) [4] - Treated patients showed a 20% reduction in major adverse cardiovascular events compared to controls [4] Efficacy Signals - A subgroup of randomized patients with elevated NTproBNP before enrollment (n=57) demonstrated strong efficacy signals [5] - Quality of life improved by 17.4 points (p=0.039) for treated patients compared to controls [4] Future Prospects - The ongoing regulatory discussions in Japan and the United States will determine the next steps for CardiAMP Cell Therapy [2][4]

Core Insights - BioCardia, Inc. is a global leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases [2] - The company will present at the CSI Focus Devices in Heart Failure conference in Frankfurt, Germany, on December 5, 2025 [1] - The presentation will focus on "Intramyocardial Cell Therapy for Ischemic Heart Failure of Reduced Ejection" [1] Company Overview - BioCardia is headquartered in Sunnyvale, California, and specializes in biotherapeutic platforms, including CardiAMP® autologous and CardiALLO™ allogeneic cell therapies [2] - The company has three clinical stage product candidates in development, supported by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms [2] Event Details - The CSI Focus D-HF conference will cover advancements in device-based therapy for heart failure, including ventricle restoration strategies and monitoring systems [1] - The session featuring BioCardia's CEO will take place from 10:30 to 11:30 CET [1]

Core Insights - BioCardia, Inc. has appointed Farhan Shahab as Vice President of Quality, bringing over 25 years of experience in executive roles related to quality and regulatory affairs [1][2]. Company Overview - BioCardia is a global leader in cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases [1][3]. - The company has two main biotherapeutic platforms: CardiAMP® (autologous cell therapy) and CardiALLO™ (allogeneic cell therapy), with three clinical stage product candidates currently in development [3]. Leadership and Expertise - Farhan Shahab previously held significant roles at Welldoc, Intuity Medical, Moximed, and AngioScore, focusing on quality assurance and regulatory compliance [2]. - Shahab's expertise in product quality management and regulatory submissions is expected to enhance BioCardia's ability to commercialize its investigational products [3].

Core Insights - BioCardia, Inc. has initiated the enrollment of the first patient in its Phase 3 CardiAMP HF II clinical trial targeting ischemic heart failure with reduced ejection fraction (HFrEF) [1][2] - The CardiAMP HF II trial aims to confirm the safety and efficacy of the CardiAMP autologous cell therapy, which has shown promising results in previous studies despite not meeting the primary endpoint [2][3] - The trial is significant as it addresses a critical need for treatment options among the approximately 2 million patients in the U.S. and EU suffering from ischemic HFrEF [2][5] Company Overview - BioCardia is a leader in cellular and cell-derived therapeutics, focusing on cardiovascular and pulmonary diseases, with its headquarters in Sunnyvale, California [7] - The company is developing two main biotherapeutic platforms: CardiAMP autologous and CardiALLO allogeneic cell therapies, with three clinical stage product candidates [7] - The CardiAMP Cell Therapy has received FDA Breakthrough designation and is designed to treat microvascular dysfunction by using a patient's own bone marrow cells [5][7] Clinical Trial Details - The CardiAMP HF II study is a randomized, multicenter, placebo-controlled trial involving 250 patients, focusing on those with elevated NTproBNP levels [3] - The primary outcome measure includes all-cause death, nonfatal major adverse cardiac events, and a validated quality of life measure, similar to the previous CardiAMP HF study [3] - Advances in the trial include improved cell population analysis for treatment dosing and enhancements to the Helix system, including the FDA-approved Morph DNA steerable platform [4][5]

Core Insights - BioCardia, Inc. has enrolled its first patient in the Phase 3 CardiAMP HF II clinical trial at the University of Wisconsin School of Medicine and Public Health, focusing on the treatment of ischemic heart failure [1][2] Company Overview - BioCardia is a leader in cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases, with a focus on the CardiAMP autologous cell therapy [7] - The company is headquartered in Sunnyvale, California, and has three clinical stage product candidates in development [7] Clinical Trial Details - The CardiAMP HF II study is a 250-patient randomized multicenter, placebo-controlled trial designed to evaluate the safety and efficacy of CardiAMP cell therapy in patients with ischemic heart failure with reduced ejection fraction (HFrEF) [3] - The trial aims to confirm previous safety and efficacy results observed in the earlier CardiAMP HF study, utilizing a composite primary outcome measure that includes all-cause death, nonfatal major adverse cardiac events, and a validated quality of life measure [3] Therapeutic Approach - CardiAMP cell therapy has received FDA Breakthrough designation and involves using a patient's own bone marrow cells delivered to the heart through a minimally invasive procedure [5] - The therapy aims to increase capillary density and reduce tissue fibrosis, addressing microvascular dysfunction in heart failure patients [5] Technological Advancements - The trial incorporates advancements such as cell population analysis for treatment dose definition and improvements to the Helix system, including the FDA-approved Morph DNA steerable platform [4]

Core Insights - BioCardia, Inc. has had a positive preliminary clinical consultation with Japan's PMDA regarding the CardiAMP Heart Failure Trial results, which is a step towards formal clinical consultation for regulatory approval [1][2][3] - The PMDA has requested additional details on various aspects of the trial, including statistical power and risk-benefit profiles, indicating a thorough review process [2] - BioCardia aims to provide access to its therapies for patients with significant needs, particularly those with limited treatment options, as highlighted by the benefits observed in the CardiAMP HF study [3] Company Overview - BioCardia, Inc. is a leader in cellular and cell-derived therapeutics focused on cardiovascular and pulmonary diseases, with its headquarters in Sunnyvale, California [4] - The company is developing three cardiac clinical stage product candidates, utilizing its Helix™ biotherapeutic delivery and Morph vascular navigation platforms, along with the upcoming Heart3D™ fusion imaging platform [4] - BioCardia selectively partners with other organizations to enhance biotherapeutic delivery and develop important biologic therapies [4]

Group 1 - BioCardia, Inc. announced a public offering of 4,800,000 shares of common stock and short-term warrants at a combined price of $1.25 per share [1][3] - The gross proceeds from the offering are expected to be $6 million, with an additional potential $6 million from the exercise of short-term warrants [3] - The company plans to use the net proceeds for working capital and general corporate purposes, including advancing investigational biotherapeutic candidates [3][6] Group 2 - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2] - The offering is being conducted under a registration statement on Form S-1, which was declared effective by the SEC on September 18, 2025 [4] - BioCardia is a leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with three clinical stage product candidates in development [6]